Malvern Instruments and Netzsch Grinding & Dispersing Sign Agreement to Cooperate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Malvern Instruments and Netzsch Grinding & Dispersing Sign Agreement to Cooperate


UK-based Malvern Instruments and Germany-based Netzsch Grinding & Dispersing have entered into a cooperative marketing agreement for a broad range of market sectors, including pharmaceuticals, announced Netzsch in an April 23 press release.

The global agreement, initially in place for three years, will harness the strength of each company’s brands and unique expertise in materials processing and materials characterization. Under the terms of the agreement, Netzsch will standardize on Malvern’s particle-sizing and characterization equipment, primarily the Mastersizer 3000 laser diffraction particle size analyzer. Customers and prospective customers of each company will gain access both to the extensive milling knowledge of the Netzsch teams and to the particle sizing know-how of Malvern Instruments.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here